September 15, 2020
US biotech Incyte has filed a new drug application (NDA) in Japan for its cholangiocarcinoma treatment pemigatinib, also known by its trade name Pemazyre overseas, the company’s local unit, Incyte Biosciences Japan, said on September 14. Pemigatinib is a selective,...read more